Literature DB >> 17661673

Human monkeypox: an emerging zoonotic disease.

Scott Parker1, Anthony Nuara, R Mark L Buller, Denise A Schultz.   

Abstract

Zoonotic monkeypox virus is maintained in a large number of rodent and, to a lesser extent, nonhuman primate species in West and central Africa. Although monkeypox virus was discovered in 1958, the prototypic human cases were not witnessed until the early 1970s. Before this time, it is assumed that infections were masked by smallpox, which was then widely endemic. Nevertheless, since the 1970s, reported monkeypox virus infections of humans have escalated, as have outbreaks with reported human-to-human transmission. This increase is likely due to numerous factors, such as enhanced surveillance efforts, environmental degradation and human urbanization of areas where monkeypox virus is maintained in its animal reservoir(s) and, consequently, serve as a nidus for human infection. Furthermore, viral genetic predispositions enable monkeypox virus to infect many animal species, represented in expansive geographic ranges. Monkeypox virus was once restricted to specific regions of Africa, but its environ has expanded, in one case intercontinentally--suggesting that human monkeypox infections could continue to intensify. As a zoonotic agent, monkeypox virus is far less sensitive to typical eradication measures since it is maintained in wild-animal populations. Moreover, human vaccination is becoming a less viable option to control poxvirus infections in today's increasingly immunocompromised population, particularly with the emergence of HIV in Sub-Saharan Africa. An increased frequency of human monkeypox virus infections, especially in immunocompromised individuals, may permit monkeypox virus to evolve and maintain itself independently in human populations.

Entities:  

Mesh:

Year:  2007        PMID: 17661673     DOI: 10.2217/17460913.2.1.17

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  90 in total

1.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

2.  Evaluation of monkeypox disease progression by molecular imaging.

Authors:  Julie Dyall; Reed F Johnson; Dar-Yeong Chen; Louis Huzella; Dan R Ragland; Daniel J Mollura; Russell Byrum; Richard C Reba; Gerald Jennings; Peter B Jahrling; Joseph E Blaney; Jason Paragas
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

3.  Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Richard Hauhart; Celia J Fang; Paula Bertram; John P Atkinson
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

4.  The poxvirus A35 protein is an immunoregulator.

Authors:  Kristina E Rehm; Gwendolyn J B Jones; Alice A Tripp; Mark W Metcalf; Rachel L Roper
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

5.  Exposure of rhesus monkeys to cowpox virus Brighton Red by large-particle aerosol droplets results in an upper respiratory tract disease.

Authors:  Reed F Johnson; Dima A Hammoud; Donna L Perry; Jeffrey Solomon; Ian N Moore; Matthew G Lackemeyer; Jordan K Bohannon; Philip J Sayre; Mahnaz Minai; Amy B Papaneri; Katie R Hagen; Krisztina B Janosko; Catherine Jett; Kurt Cooper; Joseph E Blaney; Peter B Jahrling
Journal:  J Gen Virol       Date:  2016-05-09       Impact factor: 3.891

6.  Orthopox Viruses: Infections in Humans.

Authors:  Georg Pauli; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

7.  Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets.

Authors:  Xiangzhi Meng; Thomas Kaever; Bo Yan; Paula Traktman; Dirk M Zajonc; Bjoern Peters; Shane Crotty; Yan Xiang
Journal:  Virology       Date:  2018-03-17       Impact factor: 3.616

8.  A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection.

Authors:  Marit Kramski; Kerstin Mätz-Rensing; Christiane Stahl-Hennig; Franz-Josef Kaup; Andreas Nitsche; Georg Pauli; Heinz Ellerbrok
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

Review 9.  Killing a killer: what next for smallpox?

Authors:  Grant McFadden
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

10.  Analysis of vaccinia virus-host protein-protein interactions: validations of yeast two-hybrid screenings.

Authors:  Leiliang Zhang; Nancy Y Villa; Masmudur M Rahman; Sherin Smallwood; Donna Shattuck; Chris Neff; Max Dufford; Jerry S Lanchbury; Joshua Labaer; Grant McFadden
Journal:  J Proteome Res       Date:  2009-09       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.